112 related articles for article (PubMed ID: 10958895)
21. Role of 5-lipoxygenase pathway in the regulation of RAW 264.7 macrophage proliferation.
Nieves D; Moreno JJ
Biochem Pharmacol; 2006 Oct; 72(8):1022-30. PubMed ID: 16934759
[TBL] [Abstract][Full Text] [Related]
22. Nonredundant roles for leukotriene B4 receptors BLT1 and BLT2 in inflammatory arthritis.
Mathis SP; Jala VR; Lee DM; Haribabu B
J Immunol; 2010 Sep; 185(5):3049-56. PubMed ID: 20656922
[TBL] [Abstract][Full Text] [Related]
23. An in vivo approach showing the chemotactic activity of leukotriene B(4) in acute renal ischemic-reperfusion injury.
Noiri E; Yokomizo T; Nakao A; Izumi T; Fujita T; Kimura S; Shimizu T
Proc Natl Acad Sci U S A; 2000 Jan; 97(2):823-8. PubMed ID: 10639164
[TBL] [Abstract][Full Text] [Related]
24. Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: in vitro studies.
Jackson WT; Froelich LL; Boyd RJ; Schrementi JP; Saussy DL; Schultz RM; Sawyer JS; Sofia MJ; Herron DK; Goodson T; Snyder DW; Pechous PA; Spaethe SM; Roman CR; Fleisch JH
J Pharmacol Exp Ther; 1999 Jan; 288(1):286-94. PubMed ID: 9862783
[TBL] [Abstract][Full Text] [Related]
25. Arachidonic acid activates phospholipase D in human neutrophils; essential role of endogenous leukotriene B4 and inhibition by adenosine A2A receptor engagement.
Grenier S; Flamand N; Pelletier J; Naccache PH; Borgeat P; Bourgoin SG
J Leukoc Biol; 2003 Apr; 73(4):530-9. PubMed ID: 12660228
[TBL] [Abstract][Full Text] [Related]
26. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
27. Activation of leukotriene synthesis in human neutrophils by exogenous arachidonic acid: inhibition by adenosine A(2a) receptor agonists and crucial role of autocrine activation by leukotriene B(4).
Surette ME; Krump E; Picard S; Borgeat P
Mol Pharmacol; 1999 Nov; 56(5):1055-62. PubMed ID: 10531413
[TBL] [Abstract][Full Text] [Related]
28. Synergistic effects of pranlukast and leukotriene B4 receptor antagonist on antigen-induced pulmonary reaction.
Sakurada T; Abe M; Kodani M; Sakata N; Katsuragi T
Eur J Pharmacol; 1999 Apr; 370(2):153-9. PubMed ID: 10323264
[TBL] [Abstract][Full Text] [Related]
29. Study of the role of leukotriene B()4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition.
Paredes Y; Massicotte F; Pelletier JP; Martel-Pelletier J; Laufer S; Lajeunesse D
Arthritis Rheum; 2002 Jul; 46(7):1804-12. PubMed ID: 12124864
[TBL] [Abstract][Full Text] [Related]
30. 5-Lipoxygenase inhibitory and antihistamine activities of linetastine.
Shizawa T; Ohmori S; Maeda K; Sakata K; Ishii T; Kamitani T
Arzneimittelforschung; 1996 Nov; 46(11):1072-6. PubMed ID: 8955867
[TBL] [Abstract][Full Text] [Related]
31. Immunosuppressive effect of leukotriene B(4) receptor antagonist in vitro.
Morita H; Takeda K; Yagita H; Okumura K
Biochem Biophys Res Commun; 1999 Oct; 264(2):321-6. PubMed ID: 10529362
[TBL] [Abstract][Full Text] [Related]
32. Modulation by lipid mediators of immune complex-induced lung inflammation in mice.
Steil AA; Tavares de Lima W; Jancar S
Eur J Pharmacol; 1998 Nov; 361(1):93-9. PubMed ID: 9851546
[TBL] [Abstract][Full Text] [Related]
33. Role of leukotriene B4 receptors in rheumatoid arthritis.
Mathis S; Jala VR; Haribabu B
Autoimmun Rev; 2007 Nov; 7(1):12-17. PubMed ID: 17967719
[TBL] [Abstract][Full Text] [Related]
34. Ccl2 and Ccl3 mediate neutrophil recruitment via induction of protein synthesis and generation of lipid mediators.
Reichel CA; Rehberg M; Lerchenberger M; Berberich N; Bihari P; Khandoga AG; Zahler S; Krombach F
Arterioscler Thromb Vasc Biol; 2009 Nov; 29(11):1787-93. PubMed ID: 19608967
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation.
Kirchner T; Argentieri DC; Barbone AG; Singer M; Steber M; Ansell J; Beers SA; Wachter MP; Wu W; Malloy E; Stewart A; Ritchie DM
J Pharmacol Exp Ther; 1997 Aug; 282(2):1094-101. PubMed ID: 9262379
[TBL] [Abstract][Full Text] [Related]
36. Targeted disruption of leukotriene B4 receptors BLT1 and BLT2: a critical role for BLT1 in collagen-induced arthritis in mice.
Shao WH; Del Prete A; Bock CB; Haribabu B
J Immunol; 2006 May; 176(10):6254-61. PubMed ID: 16670336
[TBL] [Abstract][Full Text] [Related]
37. Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism.
Muñoz NM; Douglas I; Mayer D; Herrnreiter A; Zhu X; Leff AR
Am J Respir Crit Care Med; 1997 Apr; 155(4):1398-403. PubMed ID: 9105085
[TBL] [Abstract][Full Text] [Related]
38. (E)-3-(3,4-Dimethoxyphenyl)-1-(5-hydroxy-2,2-dimethyl-2H-chromen-6-yl)prop-2-en-1-one ameliorates the collagen-arthritis via blocking ERK/JNK and NF-κB signaling pathway.
Li X; Peng F; Xie C; Wu W; Han X; Chen L
Int Immunopharmacol; 2013 Dec; 17(4):1125-33. PubMed ID: 24135236
[TBL] [Abstract][Full Text] [Related]
39. Cytosolic phospholipase A2 alpha inhibitor, pyrroxyphene, displays anti-arthritic and anti-bone destructive action in a murine arthritis model.
Tai N; Kuwabara K; Kobayashi M; Yamada K; Ono T; Seno K; Gahara Y; Ishizaki J; Hori Y
Inflamm Res; 2010 Jan; 59(1):53-62. PubMed ID: 19655230
[TBL] [Abstract][Full Text] [Related]
40. Role of the low-affinity leukotriene B4 receptor BLT2 in VEGF-induced angiogenesis.
Kim GY; Lee JW; Cho SH; Seo JM; Kim JH
Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):915-20. PubMed ID: 19286633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
